Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema
Sponsor: LEO Pharma
Terminated
Due to business strategic reasons, LEO Pharma has decided to close down the FCF-38 trial.
Listed as NCT03395132, this PHASE3 trial focuses on Infected Atopic Dermatitis/Eczema and remains terminated or withdrawn. Sponsored by LEO Pharma, it has been updated 12 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
▶ Show 7 earlier versions
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE3
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- LEO Pharma
For direct contact, visit the study record on ClinicalTrials.gov .